A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolarity type I
Medication studyAges 18–75
The study in practice
Understand this study
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarity
Things to check before joining
Study start dateSeptember 2012
Recruitment status
Withdrawn
Enrollment listed in the registry
0
Sponsor
Takeda
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
From 18 Years to 75 Years
Official registry ID
NCT01685151
Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects
Questions about this study?
The HopeStage team will email you.
Recruitment & locations
Withdrawn
Locations not listed
FAQ
Questions about this study
Who is behind this study?
The study sponsor is Takeda.
Does this study involve medication?
Yes. The study involves medication, including Ramelteon SL (Dose 1), Ramelteon SL (Dose 2) and Placebo.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.